Anagrelide (Agrylin)

General information

Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.
Route: PO
Extravasation: n/a

• Example of usage: Anagrelide (Agrylin) 0.5 mg PO four times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.

Diseases for which it is used

• Essential thrombocythemia
• Polycythemia vera

Patient drug information

• Anagrelide (Agrylin) patient drug information (Chemocare)
• Anagrelide (Agrylin) patient drug information (UpToDate)

History of changes in EMA indication

• 2004-11-15: Initial approval as Xagrid for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient is defined by one or more of the following features: 60 years of age or more; a platelet count 1000 x 10⁹/l or more; or a history of thrombohaemorrhagic events.

History of changes in FDA indication

• 1997-03-14: Initial approval
• 1998-12-16 (oldest label available online): Approved for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic event.

History of changes in PMDA indication

• 2014-09-26: Initial approval for the treatment of essential thrombocythemia.

Also known as

• Brand names: Agrylin, Xagrid